Replies to post #311 on Aptose Biosciences Inc (APTO)

[Tartiaboy]

In the case of TUSP monotherapy I am not sure there is an "alternative therapy" to compare with. The patients in the expansion arm have exhausted all currently available therapies and have an average of 3-4 months to live. It will be interesting to see guidance from FDA on this.